期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 30, 期 5, 页码 525-532出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.33.3716
关键词
-
类别
资金
- Cancer Research UK [C480/A7421]
- European Union [LSHC-CT-2007-037665]
- AstraZeneca
- Academy of Medical Sciences (AMS) [AMS-SGCL7-Krebs] Funding Source: researchfish
- National Institute for Health Research [CL-2011-06-002] Funding Source: researchfish
Purpose Circulating tumor cells (CTCs) may have utility as surrogate biomarkers and virtual biopsies. We report the clinical significance and molecular characteristics of CTCs and CTC clusters, termed circulating tumor microemboli (CTM), detected in patients with small-cell lung cancer (SCLC) undergoing standard treatment. Patients and Methods Serial blood samples from 97 patients receiving chemotherapy were analyzed using EpCam-based immunomagnetic detection and a filtration-based technique. Proliferation status (Ki67) and apoptotic morphology were examined. Associations of CTC and CTM number with clinical factors and prognosis were determined. Results CTCs were present in 85% of patients (77 of 97 patients) and were abundant (mean +/- standard deviation = 1,589 +/- 5,565). CTM and apoptotic CTCs were correlated with total CTC number and were detected in 32% and 57% of patients, respectively. Pretreatment CTCs, change in CTC number after one cycle of chemotherapy, CTM, and apoptotic CTCs were independent prognostic factors. Overall survival was 5.4 months for patients with >= 50 CTCs/7.5 mL of blood and 11.5 months (P < .0001) for patients with less than 50 CTCs/7.5 mL of blood before chemotherapy (hazard ratio = 2.45; 95% CI, 1.39 to 4.30; P = .002). Subpopulations of apoptotic and of proliferating solitary CTCs were detected, whereas neither were observed within cell clusters (CTM), implicating both protection from anoikis and relative resistance to cytotoxic drugs for cells within CTM. Conclusion Both baseline CTC number and change in CTC number after one cycle of chemotherapy are independent prognostic factors for SCLC. Molecular comparison of CTCs to cells in CTM may provide novel insights into SCLC biology. J Clin Oncol 30: 525-532. (C) 2012 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据